AbCellera Biologics (ABCL) Competitors $2.41 -0.08 (-3.21%) Closing price 04:00 PM EasternExtended Trading$2.46 +0.05 (+2.07%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. MOR, SRRK, CRNX, PTGX, SWTX, OGN, CPRX, VKTX, XENE, and MLTXShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include MorphoSys (MOR), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. MorphoSys Scholar Rock Crinetics Pharmaceuticals Protagonist Therapeutics SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys (NASDAQ:MOR) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Is MOR or ABCL more profitable? MorphoSys has a net margin of -226.79% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% AbCellera Biologics -533.32%-15.73%-12.22% Does the MarketBeat Community favor MOR or ABCL? AbCellera Biologics received 31 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 75.68% of users gave AbCellera Biologics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformMorphoSysOutperform Votes2538.46% Underperform Votes4061.54% AbCellera BiologicsOutperform Votes5675.68% Underperform Votes1824.32% Do institutionals & insiders have more ownership in MOR or ABCL? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 28.0% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, MOR or ABCL? MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Do analysts rate MOR or ABCL? AbCellera Biologics has a consensus target price of $7.50, indicating a potential upside of 201.81%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger valuation and earnings, MOR or ABCL? AbCellera Biologics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45AbCellera Biologics$28.83M25.68-$146.40M-$0.55-4.52 Does the media favor MOR or ABCL? In the previous week, AbCellera Biologics had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for AbCellera Biologics and 0 mentions for MorphoSys. AbCellera Biologics' average media sentiment score of 0.97 beat MorphoSys' score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral AbCellera Biologics Positive SummaryAbCellera Biologics beats MorphoSys on 15 of the 18 factors compared between the two stocks. Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$743.18M$6.85B$5.55B$8.05BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-4.097.4722.7418.81Price / Sales25.68261.18406.26107.19Price / CashN/A65.8538.1834.62Price / Book0.636.616.814.35Net Income-$146.40M$143.37M$3.22B$247.85M7 Day Performance-3.31%3.83%2.33%2.85%1 Month Performance11.94%6.22%3.68%4.29%1 Year Performance-35.45%-2.23%16.88%5.92% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.5487 of 5 stars$2.41-3.2%$7.50+211.2%-34.1%$718.15M$28.83M-3.95500Upcoming EarningsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0653 of 5 stars$29.96-2.6%$42.67+42.4%+119.0%$2.84B$33.19M-12.75140Upcoming EarningsInsider TradeNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6856 of 5 stars$30.42flat$73.00+140.0%-25.6%$2.83B$1.04M-8.16210Upcoming EarningsNews CoveragePositive NewsPTGXProtagonist Therapeutics3.4926 of 5 stars$46.04-0.5%$65.44+42.1%+76.0%$2.83B$434.43M17.31120Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9466 of 5 stars$37.42-1.3%$73.20+95.6%-1.3%$2.80B$191.59M-10.75230Analyst ForecastGap UpOGNOrganon & Co.4.7885 of 5 stars$10.60-4.7%$20.60+94.3%-49.9%$2.73B$6.40B3.1810,000Earnings ReportAnalyst DowngradeOptions VolumeNews CoverageCPRXCatalyst Pharmaceuticals4.7032 of 5 stars$22.10-1.9%$32.29+46.1%+59.7%$2.70B$491.73M18.7380Upcoming EarningsPositive NewsVKTXViking Therapeutics4.5288 of 5 stars$23.85-0.4%$89.75+276.3%-62.6%$2.68BN/A-23.8520Analyst UpgradeOptions VolumeAnalyst RevisionXENEXenon Pharmaceuticals2.589 of 5 stars$34.94-0.5%$56.78+62.5%-10.4%$2.67B$9.43M-12.39210Upcoming EarningsOptions VolumeNews CoverageMLTXMoonLake Immunotherapeutics1.5442 of 5 stars$40.03+4.4%$80.50+101.1%-3.3%$2.56BN/A-31.032Upcoming EarningsAnalyst ForecastPositive News Related Companies and Tools Related Companies MorphoSys Competitors Scholar Rock Competitors Crinetics Pharmaceuticals Competitors Protagonist Therapeutics Competitors SpringWorks Therapeutics Competitors Organon & Co. Competitors Catalyst Pharmaceuticals Competitors Viking Therapeutics Competitors Xenon Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABCL Stock Free ABCL Stock Alerts